Tools for Streamlining Cell Line Development
On-demand Webinar
Approximately 70% of all recently approved biopharmaceuticals were recombinant proteins expressed from mammalian cell lines. In turn, the need for more stable, scalable, and high-titer cell lines is on the rise. With the global cell line development (CLD) market estimated to currently be worth $4.0 billion (CAGR ~10-12%), this demand shows no signs of slowing down. More and more companies and institutions are looking for ways to streamline and expedite the CLD process in-house to meet market demand.
This webinar provides an overview of the CLD workflow and tips for choosing the right tools and techniques to optimize your in-house processes. Select instruments are highlighted, such as the iQue®, Octet®, and Ambr® 15 with demonstrates showing how these tools can be used in concert for earlier and faster clone selection, deeper analysis, and automation.
Learning Objectives:
- Understand the CLD workflow and the pain points at each stage for customers performing in-house CLD
- Understand the key features of the iQue®, Octet®, & Ambr® 15 systems and how they can accelerate and streamline the in-house CLD process
Stuart Knowling, Ph.D.
Senior Scientist
Sartorius
Stuart Knowling, Ph.D., is a Senior Scientist in the Applications Group at Sartorius. With nearly twenty years of experience in biophysical protein and nucleic acid production and characterization, Stuart also has over a decade of experience in surface plasmon resonance (SPR). He has led multiple projects for drug companies in preparation for regulatory submissions.